Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients.

Francesco PassigliaAntonio GalvanoMarta CastigliaLorena IncorvaiaValentina CalòAngela ListìSalvatore MazzarisiAlessandro PerezGiuseppe GallinaSergio RizzoHector Soto ParraViviana BazanAntonio Russo

Published in: Therapeutic advances in medical oncology (2019)

An early combined increase of both cfDNA and NLR over the course of the first 6 weeks of nivolumab therapy predicted worse survival in pretreated patients with advanced NSCLC, suggesting a potential role in the real-time monitoring of immunotherapy resistance.

Keyphrases

small cell lung cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
randomized controlled trial
advanced non small cell lung cancer
systematic review
prognostic factors
stem cells
gestational age
replacement therapy